triphenyl-(pyridin-3-yl-methyl)-phosphonium chloride | 79296-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: triphenyl-(pyridin-3-yl-methyl)-phosphonium chloride
• 英文别名: (pyridin-3-ylmethyl)triphenylphosphonium chloride；triphenyl(pyridin-3-ylmethyl)phosphonium chloride；(3-pyridyl)methyltriphenylphosphonium chloride；triphenyl(3-pyridylmethyl)phosphonium chloride；(pyridin-3-yl)-methyl-triphenylphosphonium chloride；triphenyl(pyridin-3-yl-methyl)phosphonium chloride；Phosphonium, triphenyl(3-pyridinylmethyl)-, chloride；triphenyl(pyridin-3-ylmethyl)phosphanium;chloride
• CAS: 79296-92-7
• 化学式: C₂₄H₂₁NP*Cl
• 分子量: 389.864
• InChiKey: YFOFTOVBTCVSGV-UHFFFAOYSA-M

物化性质

• 熔点：
  309-310 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.58
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  triphenyl-(pyridin-3-yl-methyl)-phosphonium chloride 在 palladium on activated charcoal 正丁基锂 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 0.5h， 生成 1-(3-Hydroxyphenyl)-2-(3-pyridinyl)ethane
  参考文献：
  名称：

  Thromboxane A2 synthase inhibitors. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acids

  摘要：

  The synthesis and screening of a series of 5-(3-pyridylmethyl)benzofuran-2-carboxylic acids as selective thromboxane A2 (TxA2) synthase inhibitors is outlined. The ability of these compounds to inhibit TxA2 biosynthesis was assayed using microsomal enzyme from human platelets. Substitution of the benzofuran ring caused small changes in potency; modification of the carboxylic acid group caused modest reductions in potency, and substitution of the pyridine ring resulted in large reductions of potency. 5-(3-Pyridylmethyl)benzofuran-2-carboxylic acid sodium salt (9b, sodium furegrelate) was chosen for further evaluation as a TxA2 synthase inhibitor.

  DOI：

  10.1021/jm00158a024
• 作为产物：
  描述：

  三苯基膦 在 potassium carbonate 作用下， 以 水 、 xylene 为溶剂， 以48%的产率得到triphenyl-(pyridin-3-yl-methyl)-phosphonium chloride
  参考文献：
  名称：

  [EN] INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS
  [FR] DERIVES D'INDENE UTILISES EN TANT QU'AGENTS PHARMACEUTIQUES

  摘要：

  化合物的公式（Ia）：其中R1、R2、R3、R4a、R4b、R5和R6的定义如本文所述，以及其他茚衍生物在此披露。还披露了含有这些化合物的药物组合物和使用这些化合物的方法。

  公开号：

  WO2004092100A1

文献信息

• (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and
  申请人：Ciba-Geigy Corporation

  公开号：US05025025A1

  公开（公告）日：1991-06-18

  Disclosed are the compounds of formula ##STR1## wherein A represents lower alkylene; B represents oxygen, sulfur, lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl-, sulfonyl- or thio)-lower alkylene, lower alkenylene, phenylene or a direct bond; M represents lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl, sulfonyl- or thio)-lower alkylene, lower alkenylene or a direct bond; or one of A, B and M represents lower alkylidenylene and the other two independently represent lower alkylene; R represents hydrogen unless A, B or M represents lower alkylidenylene in which case R represents the second bond to the adjacent aklylidenylene unsaturated carbon atom; Het represents 1-imidazolyl, 3-pyridyl, or 1-imidazolyl or 3-pyridyl substituted by lower alkyl; Ar represents carbocyclic or heterocyclic aryl; pharmaceutically acceptable ester and amide derivatives thereof; the N-oxides of said compounds wherein Het represents optionally substituted pyridyl; the said compounds of formula I wherein COOH is replaced by 5-tetrazolyl; and the pharmaceutically acceptable salts; which are useful as thromboxane synthetase inhibitors and thromboxane receptor antagonists.

  揭示了以下式的化合物##STR1##其中A代表较低的烷基; B代表氧、硫、较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基、苯基或直接键; M代表较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基或直接键; 或者A、B和M中的一个代表较低的烷基亚烯基，另外两个独立地代表较低的烷基; R代表氢，除非A、B或M代表较低的烷基亚烯基，在这种情况下R代表相邻烷基亚烯基不饱和碳原子的第二键; Het代表1-咪唑基、3-吡啶基，或者被较低烷基取代的1-咪唑基或3-吡啶基; Ar代表碳环或杂环芳基; 其药学上可接受的酯和酰胺衍生物; 其中Het代表可选择取代的吡啶基的N-氧化物; 公式I中COOH被5-四唑基取代的所述化合物; 和药学上可接受的盐; 这些化合物可用作血栓素合酶抑制剂和血栓素受体拮抗剂。
• Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings
  申请人：Allergan, Inc.

  公开号：US20160289271A1

  公开（公告）日：2016-10-06

  The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.

  本发明涉及新型环孢素类似物，制备它们的方法，含有它们的药物组合物，以及利用这些类似物和含有它们的组合物治疗医疗状况的方法，包括但不限于眼部状况如干眼症。
• [EN] 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 2-CYANOISOINDOLINE POUR LE TRAITEMENT DU CANCER
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017158388A1

  公开（公告）日：2017-09-21

  The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.

  这项发明涉及公式I的新化合物，这些化合物是去泛素化酶（DUBs）和/或去泛素化酶的抑制剂。具体来说，该发明涉及抑制泛素C端水解酶7或泛素特异性肽酶7（USP7）。该发明还涉及这些化合物的制备方法以及它们在癌症治疗中的应用。
• Certain (arylsulfonamido- and imidazolyl-)-substituted carboxylic acids
  申请人：Ciba-Geigy Corporation

  公开号：US05153214A1

  公开（公告）日：1992-10-06

  The present invention is concerned with compounds of formula I ##STR1## wherein A, B, M, R, Ar and Het are as defined in the specification, pharmaceutically acceptable ester and amide derivatives thereof; N-oxides thereof, tetrazole derivatives thereof, and salts thereof. These compounds have valuable pharmacological activities, especially as inhibitors of thromboxane synthetase and as receptor antagonists of thromboxane A.sub.2 and prostaglandin H.sub.2.

  本发明涉及以下式I的化合物 ##STR1## 其中A、B、M、R、Ar和Het如规范中所定义，其药学上可接受的酯和酰胺衍生物；其N-氧化物，四唑衍生物和盐。这些化合物具有有价值的药理活性，特别是作为血栓素合酶的抑制剂和血栓素A.sub.2和前列腺素H.sub.2的受体拮抗剂。
• Brønsted acid-catalysed conjugate addition of photochemically generated α-amino radicals to alkenylpyridines
  作者：Hamish B. Hepburn、Paolo Melchiorre

  DOI：10.1039/c5cc10401g

  日期：——

  The conjugate addition of [small alpha]-amino radicals to alkenylpyridines has been accomplished by the synergistic merger of Bronsted acid and visible light photoredox catalysis. Key to reaction development was the protonation...

  通过布朗斯台德酸和可见光光氧化还原催化的协同合并，已经实现了将小α-氨基基团共轭加成到烯基吡啶上。反应发展的关键是质子化。